40 years in MS
At Biogen, we believe no other disease area holds as much need, or as much promise for medical breakthroughs, as neuroscience.
Along with some of the world's leading researchers, we're working together to transform the field of neuroscience and bring hope to the 1 billion people affected by neurological disorders worldwide.
Watch the video to see just how committed we are to innovating research, improving knowledge and providing support to those living with disease.
Celebrating 40 years in MS
This year marks the 40th anniversary of Biogen. For the past 40 years, we’ve led cutting-edge scientific research into CNS diseases of high unmet need.
One of the world’s first
Now, we’re bringing our deep scientific understanding to new medical breakthroughs.
Our mission: Pioneers in neuroscience
We’re continuing to transform neuroscience through innovation, research and development.
Our focus on neuroscience, our scientific expertise and our courage to take risks make us leaders in the research of medicines to transform neuroscience for the benefit of society.
in active studies*
*active studies include all studies between pre-Study Management Team (SMT) formation and Clinical Study Report (CSR) as defined by internal systems as of April 23, 2018.
Expanding our core
Thanks to 40 years’ experience, we’re able to offer a portfolio of therapeutic choice in MS to meet the needs of almost every patient at multiple stages of their MS journey.
Our diverse portfolio continues to grow as we actively invest in new and meaningful targets for MS – bringing access to, and value beyond, our life-changing therapies.
A trusted partner in MS
We’re supporting people living with MS, advocacy organisations and healthcare societies to improve clinical practice and patient outcomes for the benefit of the MS community.
We’re committed to working with advocacy and patient organisations as they serve the communities they represent.
And we’re listening to our patients and healthcare providers to understand their real needs and experiences in order to elevate the care of MS.
MSP-EU+-0175d. Date of preparation: April 2018.